Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer

Stereotactic body radiotherapy (SBRT), characterised by its precise and focused delivery of high doses of radiation to well-defined targets, has emerged as an effective treatment modality for oligometastatic prostate cancer (PCa). Traditionally applied to patients with a limited number of metastases (≤5) [1], SBRT offers targeted therapeutic benefits. In this case study, we present an exceptional instance wherein a patient with PCa underwent SBRT for 20 metastatic lesions concurrently. This innovative approach served as a bridge therapy, strategically used in the interim as the patient awaited the availability of the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 (177Lu-PSMA-617) vipivotide tetraxetan.